Abstract
Although considered a specific marker for Ewing’s sarcoma/peripheral neuroectodermal tumour, the MIC2 gene product (CD99) has been immunolocalised in a variety of human tumours. The present study evaluated immunohistochemically the prevalence of CD99 expression in a series of 68 neuroendocrine tumours of different gastrointestinal and pulmonary sites. We now report on membrane and/or granular cytoplasmic immunoreactivity in 25% of these tumours, independent of their anatomical sites. In lung neuroendocrine tumours, CD99 was preferentially confined to typical carcinoids (P=0.009). A statistically significant relationship was observed between the number of CD99 positive cells but not the immunostaining patterns and the presence of local invasion and/or distant metastases (P<0.001). Moreover, there was a tendency for CD99-reactive tumours to show a reduced proliferative activity expressed by a Ki67 index of 2% (P=0.119). The number of CD99 immunoreactive cells or patterns of immunoreactivity did not correlate with the presence of associated clinical syndrome or particular hormonal immunostaining. Although the molecular basis underlying CD99 expression in neuroendocrine tumours is still poorly understood, our data suggest that CD99 may be involved in cell-to-cell adhesion of neuroendocrine tumour cells and in downregulation of their proliferative activity.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 10 February 2000 / Accepted: 6 April 2000
Rights and permissions
About this article
Cite this article
Pelosi, G., Fraggetta, F., Sonzogni, A. et al. CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours. Virchows Archiv 437, 270–274 (2000). https://doi.org/10.1007/s004280000240
Issue Date:
DOI: https://doi.org/10.1007/s004280000240